Two further clinical trials are planned to confirm a vaginal gel which has shown possible in reducing the risk of HIV. The results of the first trial of the gel, which were announced in July at the XVIII International AIDS ventilation in Vienna, must be irradicable before the product can be made handy for general use. The tenofovir-based gel was found to be 39% efficient to reduce a woman's risk of attractive infected with HIV during sex in a study completed by the Centre for the AIDS Programme of groundwork in South Africa (CAPRISA), a UNAIDS Collaborating Centre on HIV interception research...

More: - Continued here